- Integrase inhibitors, a class of antiretroviral drugs targeting the integrase enzyme essential for HIV replication, are increasingly recognized as vital components of modern HIV treatment regimens in both developed and developing regions due to their potent antiviral activity, high barrier to resistance, and favorable safety profiles
- The escalating demand for integrase inhibitors is primarily fueled by rising HIV prevalence, the shift toward first-line treatment regimens including integrase strand transfer inhibitors (INSTIs), and growing global awareness and screening efforts
- North America dominated the integrase inhibitors market with the largest revenue share of 39.2% in 2024, characterized by strong healthcare infrastructure, favorable reimbursement policies, and the widespread adoption of newer-generation HIV therapies, with the U.S. leading due to high diagnosis rates and robust drug development pipelines from key pharmaceutical companies
- Asia-Pacific is expected to be the fastest growing region in the integrase inhibitors market during the forecast period due to expanding healthcare access, rising government initiatives, and increasing availability of generic antiretrovirals
- Dolutegravir segment dominated the integrase inhibitors market with a market share of 46.4% in 2024, driven by its proven efficacy, low resistance profile, and endorsement as a preferred option in international HIV treatment guidelines
